A newly published paper in Biotechniques from the laboratory of Dr Darren Tomlinson at the University of Leeds, UK, demonstrates key characteristics exhibited by Affimer reagents in capturing target proteins from complex
Immunotherapy treatments work in different ways. Some can stimulate your immune system to recognize cancer cells and work harder to vanquish them. Others use antibodies – similar to what your
Immunotherapy is a standard treatment for some types of cancer, for example melanoma that has spread. And it is in trials for other types of cancer. What is it? Immunotherapy uses
Patients with advanced non–small-cell lung cancer (NSCLC) who received immunotherapy, in particular immune checkpoint inhibitors in the first-line setting, lived longer than those who received chemotherapy, according to the findings
Although chemotherapy remains the standard treatment for small cell lung cancer (SCLC) in first- and second-line settings, notable progress in immunotherapies have recently taken place, begging the question of how
Targeted therapy is a cancer treatment that uses drugs. But it is different from traditional chemotherapy, which also uses drugs to treat cancer. Targeted therapy works by targeting the cancer’s
Antibodies represent established affinity reagents for use in the regulatory bioanalysis of biologics. Yet, these reagents are associated with limitations that often present challenges with supply, stability and batch-to-batch variation
Avacta Group plc (LON:AVCT), a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer® platform, has today announced that its Chief Executive Officer, Dr Alastair Smith, will present
Breast cancer continues to be a global health crisis. In 2018, there were an estimated 2.1 million new cases of breast cancer worldwide. In the United States alone, another life is lost
A New Approach is Needed Avacta has two proprietary therapeutic platforms positioning the company uniquely well to address the gap in cancer immunotherapies Affimer – Alternative to anti-bodies 10x smaller
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
